NASDAQ:TCDA - Tricida Stock Price, News, & Analysis

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida Inc (NASDAQ:TCDA) posted its quarterly earnings results on Thursday, November, 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.84) by $0.19. View Tricida's Earnings History.

Tricida is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Tricida.

3 Wall Street analysts have issued 12-month price objectives for Tricida's shares. Their forecasts range from $32.00 to $50.00. On average, they anticipate Tricida's share price to reach $38.6667 in the next twelve months. This suggests a possible upside of 71.2% from the stock's current price. View Analyst Price Targets for Tricida.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tricida.

Media headlines about TCDA stock have trended somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tricida earned a news sentiment score of 1.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.

Tricida saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,827,972 shares, an increase of 64.2% from the December 14th total of 1,113,350 shares. Based on an average daily volume of 296,733 shares, the days-to-cover ratio is presently 6.2 days. Approximately 6.7% of the shares of the company are short sold. View Tricida's Current Options Chain.

Some companies that are related to Tricida include GW Pharmaceuticals PLC- (GWPH), Array Biopharma (ARRY), Taro Pharmaceutical Industries (TARO), Horizon Pharma (HZNP), Evotec (EVTCY), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Agios Pharmaceuticals (AGIO), Ascendis Pharma A/S (ASND), HUTCHISON CHINA/S (HCM), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Blueprint Medicines (BPMC), ACADIA Pharmaceuticals (ACAD) and Ultragenyx Pharmaceutical (RARE).

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Tricida's lock-up period expired on Tuesday, December 25th. Tricida had issued 11,700,000 shares in its initial public offering on June 28th. The total size of the offering was $222,300,000 based on an initial share price of $19.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $22.59.

Tricida has a market capitalization of $978.56 million. Tricida employs 61 workers across the globe.

The official website for Tricida is http://www.tricida.com.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]